SAB Biotherapeutics Secures SAB-142 Manufacturing Pact with Emergent, Committing to $36M Post-Approval Minimum
SABS has more than doubled off its 52-week low of $1.53.
Summary
SAB Biotherapeutics has entered a Master Manufacturing Services Agreement with Emergent BioSolutions Canada for the production of its lead Type 1 Diabetes candidate, SAB-142. This five-year agreement, effective upon FDA approval, includes a minimum aggregate spend of $36 million. This manufacturing pact follows the company's recent positive Phase 1 clinical data for SAB-142, as reported on April 22nd. Securing a manufacturing partner is a critical de-risking step for SAB-142's potential commercialization, demonstrating progress towards bringing the drug to market. Investors will now watch for further clinical trial advancements and regulatory milestones for SAB-142.
At the time of this announcement, SABS was trading at $3.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $188M. The 52-week trading range was $1.53 to $6.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.